C9-Functionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological α-Synuclein Aggregation and Neuroinflammation in Parkinson's Disease Degeneration
ChemMedChem. 2024 Mar 25:e202300597. doi: 10.1002/cmdc.202300597. Online ahead of print.ABSTRACTDoxycycline, a semi-synthetic tetracycline, is a widely used antibiotic for treating mild-to-moderate infections, including skin problems. However, its anti-inflammatory and antioxidant properties, combined with its ability to interfere with α-synuclein aggregation, make it an attractive candidate for repositioning in Parkinson's disease. Nevertheless, the antibiotic activity of doxycycline restricts its potential use for long-term treatment of Parkinsonian patients. In the search for non-antibiotic tetracyclines that could operate against Parkinson's disease pathomechanisms, eighteen novel doxycycline derivatives were designed. Specifically, the dimethyl-amino group at C4 was reduced, resulting in limited antimicrobial activity, and several coupling reactions were performed at position C9 of the aromatic D ring, this position being one of the most reactive for introducing substituents. Using the Thioflavin-T assay, we found seven compounds were more effective than doxycycline in inhibiting α-synuclein aggregation. Furthermore, two of these derivatives exhibited better anti-inflammatory effects than doxycycline in a culture system of microglial cells used to model Parkinson's disease neuroinflammatory processes. Overall, through structure-activity relationship studies, we identified two newly designed tetracyclines as promising drug candidates for Parkinson's disease treatment.PM...
Source: ChemMedChem - Category: Chemistry Authors: Laurent Ferri é Bruno Figad ère Cl émence Rose Rodrigo Hern án Tomas-Grau Rosana Cheh ín Brenda Zabala Patrick Pierre Michel Rita Raisman-Vozari Jean-Michel Brunel Source Type: research
More News: Antidoxidants | Brain | Chemistry | Doxycycline | Men | Neurology | Parkinson's Disease | Skin | Study | Tetracycline